Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

TP53 mutations in myelodysplastic syndrome

S Misawa¹, S Horiike

¹Third Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.

Leukemia & Lymphoma

|November 1, 1996

Summary

TP53 gene mutations are present in 14% of myelodysplastic syndromes (MDS) patients at diagnosis, indicating a role in disease development. These TP53 mutations are linked to poor prognosis in MDS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Preserved autonomic function in patients with POEMS syndrome.

Journal of the neurological sciences·2012

Same author

Factors associated with the efficiency of PBSC collection in POEMS syndrome patients undergoing autologous PBSC transplantation.

Bone marrow transplantation·2011

Same author

Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS.

Neurology·2011

Same author

Cytogenetic and molecular abnormalities in myelodysplastic syndrome.

Current molecular medicine·2011

Same author

Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC.

Physical review letters·2011

Same author

Neuromuscular transmission is not impaired in axonal Guillain--Barré syndrome.

Journal of neurology, neurosurgery, and psychiatry·2010

Area of Science:

Oncology
Hematology
Molecular Biology

Background:

TP53 tumor suppressor gene mutations are implicated in various human cancers.
TP53 mutations occur in 0-25% of myelodysplastic syndromes (MDS) cases, often associated with adverse chromosomal abnormalities like -5/5q-, -7/7q-, and 17p-.
These chromosomal changes are frequently observed in therapy-related leukemias.

Purpose of the Study:

To investigate the frequency and prognostic significance of TP53 mutations in patients with myelodysplastic syndromes (MDS).
To explore the potential role of TP53 mutations in the pathogenesis of MDS.

Main Methods:

TP53 gene mutation analysis was performed on 70 patients diagnosed with MDS.
Patient data, including karyotype and clinical outcomes, were analyzed in relation to TP53 mutation status.

Main Results:

TP53 mutations were detected in 10 (14%) of the 70 MDS patients at the time of diagnosis.
Patients with TP53 mutations exhibited a poor prognosis, irrespective of subsequent leukemic transformation.
The mutational spectrum of TP53 in MDS differs from that in solid tumors like colon and lung cancer, and may be linked to carcinogen exposure.

Conclusions:

TP53 mutations are detected at diagnosis in a subset of MDS patients and are associated with poor prognosis.
The distinct TP53 mutational spectrum in MDS suggests a potential role for environmental or unknown carcinogens in its pathogenesis.
Further research is needed to elucidate the complex pathogenesis of MDS.

Related Experiment Videos